Evidence map›Paper›PMID 32239916›Full record

ArticleACS nano2020

Subcellular Mass Spectrometry Imaging and Absolute Quantitative Analysis across Organelles.

Aurélien Thomen, Neda Najafinobar, Florent Penen, Emma Kay, Pratik P Upadhyay, Xianchan Li, Nhu T N Phan, Per Malmberg, Magnus Klarqvist, Shalini Andersson and 2 more

Open access · hybridAbstract read
In one paragraph

Article in ACS nano, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Tool to Resolve Distortions in Elemental and Isotopic Imaging.Journal of the American Chemical Society · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Aurélien ThomenDepartment of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, 412 96, Sweden.
Neda NajafinobarMedicinal Chemistry, Research and Early Development, Respiratory, Inflammation, and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 430 51, Sweden.
Florent PenenDepartment of Chemistry and Chemical Engineering, Chalmers University of Technology, Gothenburg, 412 96, Sweden.
Emma KayBioscience, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 430 51, Sweden.
Pratik P UpadhyayPharmaceutical Technolgy and Development, AstraZeneca R&D, Gothenburg, 430 52, Sweden.
Xianchan LiCenter for Imaging and Systems Biology, College of Life and Environmental Sciences, Minzu University of China, Beijing, 100081, China.
Nhu T N PhanDepartment of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, 412 96, Sweden.
Per MalmbergDepartment of Chemistry and Chemical Engineering, Chalmers University of Technology, Gothenburg, 412 96, Sweden.ORCID 0000-0002-6487-7851
Magnus KlarqvistEarly Product Development, Pharmaceutical Science, R&D, AstraZeneca, Gothenburg, 431 50, Sweden.
Shalini AnderssonNew Modalities, Discovery Sciences, R&D, AstraZeneca, Gothenburg, 430 51, Sweden.
Michael E KurczyDMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 430 51, Sweden.ORCID 0000-0001-6579-9691
Andrew G EwingDepartment of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, 412 96, Sweden.ORCID 0000-0002-2084-0133
AstraZeneca (Sweden) · SEUniversity of Gothenburg · SEChalmers University of Technology · SEMinzu University of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass spectrometry imaging is a field that promises to become a mainstream bioanalysis technology by allowing the combination of single-cell imaging and subcellular quantitative analysis. The frontier of single-cell imaging has advanced to the point where it is now possible to compare the chemical contents of individual organelles in terms of raw or normalized ion signal. However, to realize the full potential of this technology, it is necessary to move beyond this concept of relative quantification. Here we present a nanoSIMS imaging method that directly measures the absolute concentration of an organelle-associated, isotopically labeled, pro-drug directly from a mass spectrometry image. This is validated with a recently developed nanoelectrochemistry method for single organelles. We establish a limit of detection based on the number of isotopic labels used and the volume of the organelle of interest, also offering this calculation as a web application. This approach allows subcellular quantification of drugs and metabolites, an overarching and previously unmet goal in cell science and pharmaceutical development.

Indexed as

OrganellesSpectrometry, Mass, Secondary IonDiagnostic Imagingmass spectrometry imagingnanoscalenanoSIMSorganellessubcellular concentration

Identifiers

PMID32239916
PMCPMC7199216
OpenAlexW3014498020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.